

2021

Anti-Parallel β -Hairpin Structure in Soluble $A\beta$ Oligomers of $A\beta$ 40-Dutch and $A\beta$ 40-Iowa

Ziao Fu

William Van Nostrand
University of Rhode Island, wvannostrand@uri.edu

Steven O. Smith

Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs

Citation/Publisher Attribution

Fu, Z., Van Nostrand, W. E., & Smith, S. O. (2021). Anti-Parallel β -Hairpin Structure in Soluble $A\beta$ Oligomers of $A\beta$ 40-Dutch and $A\beta$ 40-Iowa. *International Journal of Molecular Sciences*, 22(3), 1225. MDPI AG. Retrieved from <http://dx.doi.org/10.3390/ijms22031225>
Available at: <https://doi.org/10.3390/ijms22031225>

This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons-group@uri.edu.

Anti-Parallel β -Hairpin Structure in Soluble A β Oligomers of A β 40-Dutch and A β 40-Iowa

Creative Commons License



This work is licensed under a [Creative Commons Attribution 4.0 License](https://creativecommons.org/licenses/by/4.0/).

Creative Commons License



This work is licensed under a [Creative Commons Attribution 4.0 License](https://creativecommons.org/licenses/by/4.0/).



Article

Anti-Parallel β -Hairpin Structure in Soluble A β Oligomers of A β 40-Dutch and A β 40-Iowa

Ziao Fu ¹, William E. Van Nostrand ^{2,3} and Steven O. Smith ^{1,*}

¹ Center for Structural Biology, Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794, USA; zfu@mail.rockefeller.edu

² George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA; wvannostrand@uri.edu

³ Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA

* Correspondence: steven.o.smith@stonybrook.edu; Tel.: +1-631-632-1210

Abstract: The amyloid- β (A β) peptides are associated with two prominent diseases in the brain, Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). A β 42 is the dominant component of cored parenchymal plaques associated with AD, while A β 40 is the predominant component of vascular amyloid associated with CAA. There are familial CAA mutations at positions Glu22 and Asp23 that lead to aggressive A β aggregation, drive vascular amyloid deposition and result in degradation of vascular membranes. In this study, we compared the transition of the monomeric A β 40-WT peptide into soluble oligomers and fibrils with the corresponding transitions of the A β 40-Dutch (E22Q), A β 40-Iowa (D23N) and A β 40-Dutch, Iowa (E22Q, D23N) mutants. FTIR measurements show that in a fashion similar to A β 40-WT, the familial CAA mutants form transient intermediates with anti-parallel β -structure. This structure appears before the formation of cross- β -sheet fibrils as determined by thioflavin T fluorescence and circular dichroism spectroscopy and occurs when AFM images reveal the presence of soluble oligomers and protofibrils. Although the anti-parallel β -hairpin is a common intermediate on the pathway to A β fibrils for the four peptides studied, the rate of conversion to cross- β -sheet fibril structure differs for each.

Keywords: Alzheimer's disease; cerebral amyloid angiopathy; amyloid- β ; A β 40-Dutch; A β 40-Iowa



Citation: Fu, Z.; Van Nostrand, W.E.; Smith, S.O. Anti-Parallel β -Hairpin Structure in Soluble A β Oligomers of A β 40-Dutch and A β 40-Iowa. *Int. J. Mol. Sci.* **2021**, *22*, 1225. <https://doi.org/10.3390/ijms22031225>

Academic Editor: Volker Knecht
Received: 31 December 2020
Accepted: 24 January 2021
Published: 27 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Sequential cleavage of the amyloid precursor protein (APP) by two proteases generates the amyloid- β (A β) peptides associated with Alzheimer's disease (AD) [1]. The first cleavage between the extracellular and the transmembrane (TM) domain of APP by β -secretase generates an N-terminal soluble fragment and a membrane-anchored C-terminal fragment (CTF) [2,3]. A second protease (γ -secretase) cleaves the CTF within the TM domain to generate the A β peptides [4,5]. The γ -secretase cleavage site is not specific. The 40-residue A β 40 peptide is the predominant cleavage product representing ~90% of the total secreted A β [6]. However, the 42-residue A β 42 peptide represents ~5–10% of secreted A β . A β 42 is considered to be the most neurotoxic form of A β , rapidly aggregates [7,8] and is the principal component of amyloid plaques in AD patients [9,10]. Either an overall increase in A β production or an increase in the A β 42/A β 40 ratio is correlated with disease progression [11].

Cerebral amyloid angiopathy (CAA) is also characterized by amyloid formation of secreted A β peptides. In CAA, amyloid deposition occurs on the cerebral blood vessels rather than in the brain parenchyma as in AD. The vascular amyloid results in loss of vessel wall integrity, which leads to vessel hemorrhaging [12–15]. In contrast to AD, the A β 40 peptide is the predominant form of A β in CAA [16,17].

In both AD and CAA, there are familial mutations in APP that enhance disease progression. Understanding how these mutations change the structure or dynamics of

APP or the A β peptides themselves can shed light on the mechanisms for A β toxicity, clearance and amyloid deposition in these two diseases. In AD, there are two major clusters of familial mutations that lead to early onset AD. The first cluster is at the β -secretase cleavage site where mutations can enhance cleavage, leading to an increase in total secreted A β [18]. The second cluster is C-terminal to the γ -secretase cleavage site, where mutations result in an increase in A β 42 relative to A β 40 [19–21]. These sets of familial AD mutants generally result in an increase in the total A β produced or in an increase in the A β 42/A β 40 ratio, rather than influencing the kinetics of A β fibril formation or the structure of the A β oligomers or fibrils.

There are several mutations at positions 22 and 23 in the middle of the A β sequence that enhance vascular amyloid deposition. A β 40-Iowa (D23N) is unique in that no additional familial mutations have been reported at position 23. In CAA cases, the A β 40-Iowa peptide preferentially deposits on microvessels and capillaries and exhibits a robust perivascular neuroinflammatory response [22]. In addition, this mutation can lead to the formation of fibrils with anti-parallel β -sheet structure in solution under low temperature and low salt conditions [23]. The fibril structures of A β 40-WT and A β 40-Iowa both exhibit a bend near position 23 that allows the hydrophobic N-terminal Leu17-Ala21 sequence to pack on the C-terminal Ile31-Val36 sequence. In mature fibrils of the A β 40-WT peptide with parallel β -sheet structure, the Asp23 side chain forms a salt bridge with Lys28 within the hydrophobic fibril core [24], while in A β 40-Iowa fibrils with anti-parallel β -sheet structure, Asn23 forms hydrogen-bonds within the fibril core, but Lys28 remains oriented outward toward solvent where it interacts electrostatically with the C-terminal carboxyl group of the neighboring peptide in the fibril [23].

Position 22, adjacent to the site of the Iowa mutation, is a second site where mutations occur that enhance CAA. Several mutations have been described at this position, including the Arctic (E22G), Italian (E22K) and Dutch (E22Q) variants. Like A β 40-Iowa, the E22K and E22G mutations dramatically enhance the rate of fibril formation [25,26]. The E22Q Dutch mutation, on the other hand, exhibits fibrillization kinetics that are only slightly faster than A β 40-WT [25,26]. This mutation is one of the first CAA mutations to be identified [27]. Both A β 40-WT and A β 40-Dutch preferentially deposit on cerebral arterioles and small arteries [27], which contrasts with the location of vascular deposition for A β 40-Iowa.

In this study, we address the mechanism(s) of fibril formation of the A β 40-Dutch and A β 40-Iowa peptides using spectroscopic methods to follow structural changes that occur in the transition from monomers to fibrils in solution. The pathways for forming these A β fibrils are of interest for several reasons. First, familial mutations at positions 22 and 23 of the A β sequence lead to faster A β aggregation and are associated with CAA [26]. In general, the rate limiting steps in fibril formation for wild-type (WT) A β and the familial A β mutants are still not well understood. Second, the A β 40-Dutch and A β 40-Iowa peptides are considerably more toxic to cultured cerebral vascular smooth muscle cells than the A β 40-WT peptide [28]. The double mutant A β 40-Dutch, Iowa (A β 40-DI) combines the Dutch and Iowa mutations in a single peptide. While this mutant is not found clinically, it serves as a point of comparison for our current studies as it forms fibrils much more rapidly and exhibits a two-fold increase in toxicity relative to either A β 40-Dutch or A β 40-Iowa [28]. Finally, soluble oligomers are generally thought to be the toxic species in AD. However, in CAA the disruption of vascular membranes may involve the formation of fibrils rather than oligomers [29,30]. One open question is whether these peptides form well-defined soluble oligomers and protofibrils, similar to A β 40-WT and A β 42-WT.

The time course from monomers to fibrils is followed using FTIR, thioflavin T fluorescence and circular dichroism (CD) spectroscopy. One of the main aims of this study was to distinguish the formation of anti-parallel β -hairpin structure in oligomers and protofibrils from anti-parallel cross- β -sheet structure in mature fibrils. Anti-parallel β -structure resulting from β -hairpin formation in soluble oligomers is often attributed to the presence of cross- β -sheet fibril structure within these oligomers. To reduce the formation of anti-parallel cross- β -sheet structure, the time course measurements were undertaken at

37 °C and with strong agitation, both of which favor the conversion to parallel, in-register fibrils. Our FTIR and thioflavin T fluorescence measurements reveal that the CAA mutant peptides rapidly form a transient anti-parallel β -hairpin intermediate, which has also been reported for the A β 40-WT [31] and A β 42-WT peptides [32]. This intermediate occurs when oligomers and protofibrils are observed by atomic force microscopy (AFM) at early time points in the fibrillization process, and when appreciable β -sheet structure has not yet formed as monitored by CD spectroscopy. That is, the anti-parallel β -hairpin structure forms prior to the observation of β -sheet-containing fibrils. β -hairpins are stabilized by intramolecular hydrogen bonding and consequently differ markedly from the anti-parallel β -sheet structure observed for A β 40-Iowa fibrils [23] or from fibrils formed using A β 40-DI seeds obtained from transgenic rats [33]. We discuss these results in terms of the pathway(s) for fibril formation, clearance, vascular amyloid formation and cellular toxicity of the A β 40-Dutch and A β 40-Iowa mutants in the aging brain.

2. Results

2.1. Monomer to Fibril Conversion of A β 40-WT

An increase of thioflavin T fluorescence at 490 nm is often used to characterize the kinetics of fibril formation of the A β peptides. The time course for fibril formation depends on several key experimental parameters including temperature, concentration and agitation [32]. The temperature (37 °C) and agitation (200 rpm shaking) conditions were chosen to facilitate the transition to fibrils having β -strands associated in a parallel orientation. A β 40-WT typically has a long lag phase prior to fibril formation compared to A β 42-WT or to A β 40 with mutations at positions 22 and 23. Under the conditions of our experiments (50 mM NaCl, 10 mM phosphate buffer, pH 7.2, 37 °C, 100 μ M A β), the lag phase observed in fluorescence experiments is ~8 h (Figure 1a). In contrast, under quiescent conditions at lower temperatures, the lag phase in A β 40-WT fibrillization is several days. The relatively short lag phase observed here is largely attributed to strong agitation of the sample. In addition, strong agitation facilitates the conversion of the A β 40-Iowa peptide to a parallel, in-register fibril structure [34]. The samples were diluted prior to measurements in order to shift the equilibrium between monomers, oligomers and protofibrils toward monomer. Under these conditions, the fluorescence readings are more reflective of stable fibrils [32].

CD and FTIR spectroscopy are both sensitive to protein secondary structure. Monomers of the A β 40-WT peptides formed at low temperature (4 °C) adopt largely random coil structure, which exhibits a negative band at ~200 nm in CD spectra. The negative ellipticity of the CD spectrum at $t = 0$ h is not strong, suggesting the presence of β -structure already at this time point (the absolute value of the negative molar ellipticity of random coil is roughly equal to the positive molar ellipticity of β -sheet at 200 nm [35,36]). An increase in temperature enhances the association of A β monomers into fibrils with β -sheet structure, seen as a positive CD absorption band between 190 and 200 nm and a broad negative CD band between 210 and 220 nm. Using these structural markers, β -sheet forms in the A β 40-WT peptide between 6 and 24 h under the conditions used (Figure 1b). These changes correlate with the increase in thioflavin T fluorescence after 8 h in Figure 1a.

We have previously shown using FTIR spectroscopy that the A β 42-WT peptide forms a transient β -hairpin prior to association into β -sheet fibrils [32]. The β -hairpin is formed by intramolecular hydrogen bonding of two anti-parallel β -strands in the A β peptide. The β -strands roughly correspond to the two hydrophobic stretches in the sequence (Leu17-Ala21 and Ile31-Val36). As with fluorescence and CD spectroscopy, the time course of fibril formation can be followed by FTIR spectroscopy. The A β 40 monomer exhibits a broad band between 1640 and 1680 cm^{-1} , characteristic of random coil. The featureless amide I band in the FTIR spectrum at $t = 0$ h for the unlabeled peptide is characteristic of random coil (e.g., it spans the amide I range of vibrational frequencies and exhibits no defined, sharp features). The formation of β -sheet results in a sharp amide I IR band at ~1630 cm^{-1} . The FTIR time series (Figure 1c) shows the transition to β -sheet in the same time frame as the CD and fluorescence measurements.




Figure 1. Fibril formation of Aβ40-WT involves a transient anti-parallel non-fibrillar intermediate. Time courses of fibril formation from monomeric Aβ40-WT at 37 °C are shown using thioflavin T fluorescence (a), circular dichroism (b) and FTIR (c,d) spectroscopy. Fibril formation monitored by thioflavin T fluorescence at 490 nm increases rapidly after ~8 h of incubation of monomeric Aβ40-WT. The peptide is largely unstructured before the increase in thioflavin T fluorescence. This is observed by both the lack of a CD signal and by the broad amide I band in the FTIR spectrum. Isotopic labeling of the Aβ40-WT peptide with 1-¹³C glycine at Gly33 in (d) results in an isotropically shifted peak at ~1618 cm⁻¹ that is characteristic of anti-parallel β-structure. We interpret the appearance and disappearance of this band as the conversion of monomeric Aβ40-WT into an anti-parallel β-hairpin that then converts into parallel, in-register β-sheet as fibrils form.

Distinguishing parallel and anti-parallel β-sheets is generally a challenge when using FTIR. A weak band at 1695 cm⁻¹ is often used as a diagnostic for anti-parallel β-sheet structure [37]. However, this band is often obscured by the broad random coil background at early time points on the pathway to fibrils. For Aβ42-WT, our approach has been to isotopically label the backbone carbonyl with ¹³C at Gly33 within the C-terminal β-strand of the peptide [32], and for C99 we have incorporated ¹³C labels in the Leu17-Ala21 sequence in the middle of the peptide sequence [38]. The ¹³C=O label results in a splitting of the amide I normal mode for anti-parallel β-sheet with an increase in the intensity of a low frequency band at ~1617 cm⁻¹ [39,40]. In parallel β-sheet with this labeling scheme, the low frequency band shifts to ~1603 cm⁻¹ and loses intensity [32]. Figure 1d presents an FTIR time series using 1-¹³C Gly33 labeled Aβ40-WT. An isotope-shifted resonance at 1618 cm⁻¹ is observed between 0 and 6 h. This resonance shifts to 1605 cm⁻¹ and loses intensity as fibrils form. These changes are similar to those observed for Aβ42-WT and are attributed to a transition from an intermediate with anti-parallel β-hairpin structure to fibrils with parallel cross-β-sheet structure [32].

2.2. A β 40-Dutch and A β 40-Iowa form Transient Anti-Parallel β -Hairpins

Several studies have previously shown that mutations at positions 22 and 23 of A β 40 result in fibrils forming much more rapidly than A β 40-WT [26,28]. On the basis of thioflavin T fluorescence (Figure 2a–c), A β 40-Dutch fibrils form within 8 h at 37 °C, while A β 40-Iowa fibrils form within 5 to 6 h under the same conditions as used for A β 40-WT in Figure 1. The combination of the Dutch and Iowa mutations in a single peptide has a markedly stronger phenotype than either of the single mutations [41]. The expression of the double mutant A β 40-DI peptide in transgenic mice decreases the age of onset of vascular amyloid deposition and increases the amount of vascular amyloid formed relative to either A β 40-Iowa or A β 40-Dutch [41]. In solution, the A β 40-DI double mutant exhibits more rapid fibril formation using thioflavin T than the single mutants (Figure 2c).




Figure 2. Fibril formation of A β 40-Iowa, Dutch and Dutch-Iowa mutants involves a transient anti-parallel non-fibrillar intermediate. Time courses of fibril formation from monomeric A β 40 peptides at 37 °C are shown using thioflavin T fluorescence (a–c), circular dichroism (d–f) and FTIR (g–i) spectroscopy. The time courses for the mutant peptide for fibril formation monitored by thioflavin T fluorescence at 490 nm is much more rapid than for A β 40-WT. However, for each peptide when labeled with $1\text{-}^{13}\text{C}$ Gly33, there is observation of a β -hairpin intermediate as fibrils form.

The time scale for fibril formation for A β 40-Dutch, A β 40-Iowa and A β 40-DI is also reflected in the time scale for β -sheet formation by CD spectroscopy (Figure 2d–f). As observed in the CD spectrum of A β 40-WT, the $t = 0$ h spectra of the familial mutants of A β 40 do not exhibit an intense random coil band at 200 nm, suggesting the presence of β -structure already in these samples, the positive ellipticity of which cancels the negative ellipticity characteristic of random coil. The absence of a negative random coil band is most

apparent for the A β 40-DI peptide, which exhibits the fastest fibrillization rate by thioflavin T fluorescence.

Using the same 1- ^{13}C Gly33 labeling scheme as used in Figure 1d, we address whether the A β 40 mutants exhibit a similar anti-parallel intermediate as in A β 40-WT. The FTIR time series of A β 40-Dutch, A β 40-Iowa and A β 40-DI reveal the transient appearance and disappearance of an isotope shifted band at $\sim 1615\text{ cm}^{-1}$ prior to fibril formation (Figure 2g–i). For all peptides, the isotope shifted band is observed at $t = 0\text{ h}$ (i.e., immediately after forming the monomers at $4\text{ }^\circ\text{C}$ and layering the sample on the ATR plate at room temperature for FTIR measurements). The intensity of the 1615 cm^{-1} band increases slightly for the A β 40-Iowa and A β 40-DI peptides before shifting and losing intensity. For A β 40-DI, the presence of both the 1600 and 1617 cm^{-1} bands were observed in the spectra obtained at 1 and 2 h prior to a shift in the low frequency band at 1600 cm^{-1} at longer times.

The spectroscopic data above define a window prior to fibril formation where there is a transient appearance of intensity in the isotope-shifted IR band attributed to β -hairpin secondary structure. In Figure 3, single touch AFM images are presented after 30 min of incubation of monomeric A β 40-Dutch and A β 40-Iowa. The images capture the formation of low molecular weight oligomers with heights of 2–3 nm that are associating to form protofibrils.




Figure 3. Single touch AFM images of A β 40-Dutch (a) and A β 40-Iowa (b). Images were obtained after 30 min of incubation at room temperature. Heights of the aggregates above the mica surface (in nm) are color-coded. Scale bars = 50 nm.

Higher molecular weight oligomers with heights of 5–7 nm are also observed, but are much less abundant and do not increase with time as observed in the pathway to fibrils using the A β 42-WT peptide [42]. Although not clear from these single images, the A β 40-Dutch peptide tends to exhibit more aggregated species than A β 40-Iowa. The fibrils formed from the protofibrils of A β 40-Iowa typically have heights of $\sim 3\text{ nm}$ [34], similar to those observed for the A β 40-Arctic mutation, but distinct from the $\sim 6\text{--}7\text{ nm}$ heights observed for A β 40-WT [43] and from the high molecular weight oligomers in A β 42-WT [42].

3. Discussion

Our current results show that the A β 40-Iowa and A β 40-Dutch peptides form a transient β -hairpin intermediate, a feature shared by wild-type A β 40 and A β 42. Evidence for an anti-parallel β -hairpin forming in A β 40-WT, A β 40-Dutch and A β 40-Iowa comes from FTIR measurements. In the FTIR spectra, the signature anti-parallel β -strand peak appears immediately after the A β 40-WT peptide is filtered and layered on the ATR plate for FTIR measurements. Nevertheless, there is substantial random coil in these peptides. Solution NMR studies on A β 40-WT indicate that the β -hairpin structure is in chemical exchange with random coil with the equilibrium in favor of the random coil structure [44]. We interpret the broad band between 1660 and 1690 cm^{-1} as random coil. The ~ 1634 and 1641 cm^{-1} bands observed for ^{13}C -labeled and unlabeled A β 40-WT are characteristic of

nascent β -strands. Mature fibrils with well-formed β -sheet exhibit a sharp amide I band from 1626 to 1630 cm^{-1} in unlabeled fibrils. The split bands at 1618 and 1634 cm^{-1} in the peptide containing a $^{13}\text{C}=\text{O}$ label at Gly33 are interpreted as arising from anti-parallel β -strands. We did not observe a defined peak at 1672 cm^{-1} characteristic of α -sheet structure [45].

The proposed β -hairpin structure associated with this transient intermediate state has intra-molecular hydrogen bonding between a β -strand centered on the hydrophobic Leu17-Ala21 and Ile31-Gly37 sequences. The model that emerges from these and other studies [31,32] is that the first step in conversion of monomeric A β into fibrils is the rapid conversion to a β -hairpin structure stabilized by intramolecular hydrogen bonding. This mechanism is likely to be concentration independent since it is an intramolecular interaction. As a result, the formation should occur at low physiological concentrations. Recent structural studies of C99 show that sequence from Tyr10 to Ala21 forms a β -hairpin that associates with the membrane bilayer [46]. As a result, the Leu17-Ala21 β -strand is primed to form a β -hairpin with the C-terminal Ile31-Gly37 sequence following γ -secretase cleavage of C99 and release of the A β peptide from the enzyme [46].

There is a wide range of data supporting the transient formation of a β -hairpin intermediate on the pathway to A β fibrils. One line of evidence comes from protein engineering studies in which β -hairpins are stabilized by an intra-molecular disulfide bond [47–49]. The CC crosslink prevents intermolecular hydrogen bonding in the cross- β -sheet structures characteristic of mature fibrils. A β 40-CC and A β 42-CC both spontaneously form stable oligomers and protofibrils, but both are unable to convert into amyloid fibrils. Conformation-specific antibodies used to detect A β aggregates in vivo indicate that the wild-type oligomer structure is preserved and stabilized in the A β -CC oligomers.

In a similar fashion, Tycko and Meredith [50] synthesized A β 40-lactam(D23/K28), which contains a lactam bridge between the side chains of Asp23 and Lys28. Rather than locking the monomer in the β -hairpin conformation, the lactam locks the monomer in the conformation the A β 40 peptide adopts in cross- β -sheet fibrils. A β 40-lactam (D23/K28) forms fibrils similar to those formed by A β 40-WT. However, fibril formation occurs without a lag phase and at a rate \sim 1000-fold greater than for A β 40-WT.

Since the formation of anti-parallel β hairpin occurs rapidly, the rate-determining step in fibril formation likely involves the rotation of the individual β -strands to form intermolecular hydrogen bonds in cross- β -sheet fibrils. For A β 40-WT, this involves the rotation of the negatively charged Asp23 and positively charged Lys28 into the hydrophobic interior of the nascent fibril where they are stabilized by salt-bridge formation. Separately, rotation of either the charged Asp23 or Lys28 side chains into the hydrophobic fibril core is energetically unfavorable, which explains the rapid fibril kinetics and lack of a lag phase when these residues are cross-linked in the A β 40-lactam (D23/K28).

In the Iowa mutant (D23N), the uncharged Asn side chain does not have this energetic barrier to rotation. In the anti-parallel fibril structure of A β 40-Iowa, Asn23 is hydrogen bonded with Gln15 and Asn27, whereas Lys28 is oriented outward where it interacts with the C-terminus of the neighboring peptide in anti-parallel fibrils [23]. The outward orientation of Lys28 is also seen in A β 42-WT where it forms a salt bridge with the negative charge on the C-terminal carboxyl group [51,52].

Unlike A β 40-Iowa, a fibril structure has not been determined for A β 40-Dutch. Solid-state NMR studies on both the E22G [53] and E22K [54] mutants suggest polymorphism in their fibril structure. For E22K, NMR experiments have shown that the structural polymorphism reflects one population where Asp23 rotates inward to form a salt bridge with Lys28 and a second population where the Asp23 side chain remains oriented outward and interacts electrostatically with the Lys22 side chain [54], indicating that there is at least one fibril population with a structure that is similar to A β 40-WT.

Although all of the peptides studied here form a transient β -hairpin intermediate with anti-parallel β -strands, the kinetics of fibril formation are quite different. Using AFM, we showed that at 100 μM A β concentration both A β 40-Iowa and A β 40-Dutch

form oligomers that predominantly have heights of 2–3 nm. These oligomers laterally associate and merge to form cross β -sheet fibrils in a fashion previously described for A β 42-WT at high A β concentrations [32]. Unlike A β 42-WT, the heights of the initial fibrils formed are lower. The oligomeric intermediates indicate that the fibrils form via nucleated conformation conversion. However, the lower heights observed for the fibrils are consistent with nucleated polymerization pathways that involve monomer addition to nucleation sites and occur at lower A β concentrations [32,55]. Fibrils with low heights are observed for A β 42-WT at low A β concentrations where there is appreciable A β monomers in solution [56]. In addition, the E22Q and D23N mutations occur close to or within the turn region in the β -hairpin and likely control the final β -hairpin structure and resulting fibrils [57].

The E22Q and D23N mutations are adjacent to one another in the A β 40 sequence and both result from substitution of a negatively charged residue to a neutral amine. One possible contributor to enhanced deposition of the familial CAA mutant peptides involves the mechanism for the clearance of the A β peptides from the brain [58,59]. In this regard, there are a number of different pathways for clearance including degradation by enzymes such as neprilysin, uptake and degradation by astrocytes and microglia, transport out of the interstitial fluid through the cerebral spinal fluid and efflux across the blood–brain barrier into the blood stream. The structure (monomer, oligomer, fibril) of the A β peptide likely determines the pathway(s) taken. Since A β 40-WT, A β 40-Dutch and A β 40-Iowa adopt a similar β -hairpin structure to the monomer, it is likely the differences in the clearance pathway(s) depend on the rate of fibril formation and stability of the protofibrils or fibrils during the aggregation process. Stable fibrils are less likely to cross membrane barriers that would be required for transport out of the interstitial brain fluid via the cerebral spinal fluid or blood stream.

4. Materials and Methods

4.1. Sample Preparation

A β peptides were synthesized using N-t-Boc-chemistry (ERI-Amyloid, Waterbury, CT, USA) and purified by high-performance liquid chromatography. The mass of the purified peptide was measured using matrix-assisted laser desorption or electrospray ionization mass spectrometry, and was consistent with the calculated mass for the peptide. On the basis of analytical reverse phase high-performance liquid chromatography and mass spectrometry, the purity of the peptides was generally >98%.

Purified, lyophilized A β 40 peptides (ERI Amyloid Laboratory, Oxford, CT, USA) were dissolved in 100 mM NaOH at a concentration of 2.2 mM, then diluted in buffer (10 mM phosphate, 50 mM NaCl) at low temperature (4 °C) and titrated to pH 7.4. The A β solutions were then filtered two times with 0.2-micron cellulose acetate filters to remove insoluble aggregates that can nucleate and influence aggregation. The A β concentrations were determined by the absorption at 270 nm using a molar extinction coefficient of $\epsilon = 1405 \text{ cm}^{-1} \cdot \text{M}^{-1}$. To initiate A β aggregation, the solutions of monomeric peptide at 4 °C were placed in a 37 °C incubator and shaken at 200 rpm. For AFM, FTIR and fluorescence measurements, aliquots of the peptide solution were removed at time points between 0 and 50 h.

4.2. FTIR Spectroscopy

FTIR spectroscopy was performed with a Bruker IFS 66V/S spectrometer with a liquid nitrogen cooled mercury–cadmium–telluride detector. Spectra were recorded with a spectral resolution of 4 cm^{-1} . The internal reflection element was a germanium ATR plate. Samples were prepared by spreading 50–100 μL of 100 μM in 10 mM phosphate and 50 mM NaCl buffer on the plate surface and by drying under N_2 or air. One thousand scans were averaged for each spectrum. For these experiments, the samples were incubated at 37 °C with 200 rpm agitation and then removed for the FTIR time points. The FTIR measurements were carried out at room temperature.

4.3. Circular Dichroism (CD) Spectroscopy

CD spectra were obtained on an Olis RSM CD spectrophotometer (Olis Inc., Bogart, GA, USA) using a 1 mm width quartz cuvette at an A β concentration of 100 μ M in 10 mM phosphate and 50 mM NaCl buffer. The temperature was maintained at 37 °C.

4.4. Thioflavin T Fluorescence Spectroscopy

Fluorescence experiments were performed using a Horiba Jobin Yvon Fluorolog FL3-22 spectrofluorometer. For these experiments, the samples were incubated at 37 °C with 200 rpm agitation as in the CD and FTIR measurements and then removed for the thioflavin T fluorescence time points. At each time point, aliquots were taken and mixed with 30 μ M thioflavin T to produce mixtures with peptide/thioflavin T ratio β of 1:20. Thioflavin T fluorescence emission spectra were obtained from 475 to 550 nm using an excitation wavelength of 461 nm.

4.5. Atomic Force Microscopy

Single touch AFM images were obtained using a MultiMode microscope (Digital Instruments, Santa Barbara, CA, USA) with a custom-built controller (LifeAFM, Port Jefferson, NY, USA) that allows one low force contact of the AFM tip to the sample surface per pixel [56]. Super-sharp silicon probes with a tip width of 3–5 nm (at a height of 2 nm) were modified for magnetic retraction by attachment of samarium cobalt particles. Samples for AFM were diluted with MilliQ water from a 100 μ M A β concentration in 10 mM phosphate and 50 mM NaCl buffer to a concentration of 0.5 μ M A β and then deposited onto freshly cleaved ruby mica (S & J Trading, Glen Oaks, NY, USA) and imaged under hydrated conditions.

Author Contributions: Conceptualization, Z.F., W.E.V.N. and S.O.S.; formal analysis, Z.F. and S.O.S.; investigation, Z.F. and S.O.S.; data curation, Z.F. and S.O.S.; writing—original draft preparation, S.O.S.; writing—review and editing, Z.F., W.E.V.N. and S.O.S.; project administration, S.O.S.; funding acquisition, S.O.S. and W.E.V.N. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Institutes of Health, grant numbers RF1 AG27317 and RO1-NS092696.

Data Availability Statement: The data presented in this study are contained within the article.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AFM	Atomic force microscopy
A β	Amyloid β
AD	Alzheimer's disease
APP	Amyloid precursor protein
CAA	Cerebral amyloid angiopathy
CTF	C-terminal fragment
FTIR	Fourier-transformed infrared
TM	Transmembrane
WT	Wild-type

References

1. Selkoe, D.J. Alzheimer's disease: Genes, proteins, and therapy. *Physiol. Rev.* **2001**, *81*, 741–766. [[CrossRef](#)] [[PubMed](#)]
2. Seubert, P.; Oltsersdorf, T.; Lee, M.G.; Barbour, R.; Blomquist, C.; Davis, D.L.; Bryant, K.; Fritz, L.C.; Galasko, D.; Thal, L.J.; et al. Secretion of β -amyloid precursor protein cleaved at the amino terminus of the β -amyloid peptide. *Nature* **1993**, *361*, 260–263. [[CrossRef](#)] [[PubMed](#)]
3. Kopan, R.; Ilagan, M.X.G. β -secretase: Proteasome of the membrane? *Nat. Rev. Mol. Cell Biol.* **2004**, *5*, 499–504. [[CrossRef](#)] [[PubMed](#)]

4. De Strooper, B.; Saftig, P.; Craessaerts, K.; Vanderstichele, H.; Guhde, G.; Annaert, W.; Von Figura, K.; Van Leuven, F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. *Nature* **1998**, *391*, 387–390. [[CrossRef](#)] [[PubMed](#)]
5. Wolfe, M.S.; Xia, W.M.; Ostaszewski, B.L.; Diehl, T.S.; Kimberly, W.T.; Selkoe, D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ -secretase activity. *Nature* **1999**, *398*, 513–517. [[CrossRef](#)]
6. Selkoe, D.J. Alzheimer disease: Mechanistic understanding predicts novel therapies. *Ann. Intern. Med.* **2004**, *140*, 627–638. [[CrossRef](#)]
7. Burdick, D.; Soreghan, B.; Kwon, M.; Kosmoski, J.; Knauer, M.; Henschen, A.; Yates, J.; Cotman, C.; Glabe, C. Assembly and aggregation properties of synthetic Alzheimer's A4/ β amyloid peptide analogs. *J. Biol. Chem.* **1992**, *267*, 546–554. [[CrossRef](#)]
8. Kienlen-Campard, P.; Miolet, S.; Tasiaux, B.; Octave, J.N. Intracellular amyloid- β 1-42, but not extracellular soluble amyloid- β peptides, induces neuronal apoptosis. *J. Biol. Chem.* **2002**, *277*, 15666–15670. [[CrossRef](#)]
9. Portelius, E.; Bogdanovic, N.; Gustavsson, M.; Volkman, I.; Brinkmalm, G.; Zetterberg, H.; Winblad, B.; Blennow, K. Mass spectrometric characterization of brain amyloid β isoform signatures in familial and sporadic Alzheimer's disease. *Acta Neuropathol.* **2010**, *120*, 185–193. [[CrossRef](#)]
10. Kakuda, N.; Miyasaka, T.; Iwasaki, N.; Nirasawa, T.; Wada-Kakuda, S.; Takahashi-Fujigasaki, J.; Murayama, S.; Ihara, Y.; Ikegawa, M. Distinct deposition of amyloid- β species in brains with Alzheimer's disease pathology visualized with MALDI imaging mass spectrometry. *Acta Neuropathol. Commun.* **2017**, *5*, 1–8. [[CrossRef](#)]
11. Borchelt, D.R.; Thinakaran, G.; Eckman, C.B.; Lee, M.K.; Davenport, F.; Ratovitsky, T.; Prada, C.M.; Kim, G.; Seekins, S.; Yager, D.; et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate A β 1-42/1-40 ratio in vitro and in vivo. *Neuron* **1996**, *17*, 1005–1013. [[CrossRef](#)]
12. Thal, D.R.; Griffin, W.S.T.; de Vos, R.A.I.; Ghebremedhin, E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. *Acta Neuropathol.* **2008**, *115*, 599–609. [[CrossRef](#)] [[PubMed](#)]
13. Auriel, E.; Greenberg, S.M. The pathophysiology and clinical presentation of cerebral amyloid angiopathy. *Curr. Athero. Rep.* **2012**, *14*, 343–350. [[CrossRef](#)] [[PubMed](#)]
14. Biffi, A.; Greenberg, S.M. Cerebral amyloid angiopathy: A systematic review. *J. Clin. Neuro.* **2011**, *7*, 1–9. [[CrossRef](#)] [[PubMed](#)]
15. Attems, J.; Jellinger, K.; Thal, D.R.; Van Nostrand, W. Sporadic cerebral amyloid angiopathy. *Neuropathol. Appl. Neurobiol.* **2011**, *37*, 75–93. [[CrossRef](#)]
16. Castano, E.M.; Prelli, F.; Soto, C.; Beavis, R.; Matsubara, E.; Shoji, M.; Frangione, B. The length of amyloid- β in hereditary cerebral hemorrhage with amyloidosis, Dutch type—Implications for the role of amyloid- β 1-42 in Alzheimer's disease. *J. Biol. Chem.* **1996**, *271*, 32185–32191. [[CrossRef](#)]
17. Roher, A.E.; Lowenson, J.D.; Clarke, S.; Woods, A.S.; Cotter, R.J.; Gowing, E.; Ball, M.J. β -amyloid-(1-42) is a major component of cerebrovascular amyloid deposits—Implications for the pathology of Alzheimer-disease. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 10836–10840. [[CrossRef](#)]
18. Johnston, J.A.; Cowburn, R.F.; Norgren, S.; Wiehager, B.; Venizelos, N.; Winblad, B.; Vigopelfrey, C.; Schenk, D.; Lannfelt, L.; O'Neill, C. Increased β -amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation. *FEBS Lett.* **1994**, *354*, 274–278. [[CrossRef](#)]
19. Xu, T.H.; Yan, Y.; Kang, Y.Y.; Jiang, Y.; Melcher, K.; Xu, H.E. Alzheimer's disease-associated mutations increase amyloid precursor protein resistance to gamma-secretase cleavage and the A β 42/A β 40 ratio. *Cell Discov.* **2016**, *2*, 1–14. [[CrossRef](#)]
20. Tang, T.C.; Kienlen-Campard, P.; Hu, Y.; Perrin, F.; Opsomer, R.; Octave, J.N.; Constantinescu, S.N.; Smith, S.O. Influence of the familial Alzheimer's disease-associated T43I mutation on the transmembrane structure and -secretase processing of the C99 peptide. *J. Biol. Chem.* **2019**, *294*, 5854–5866. [[CrossRef](#)]
21. Yan, Y.; Xu, T.H.; Harikumar, K.G.; Miller, L.J.; Melcher, K.; Xu, H.E. Dimerization of the transmembrane domain of amyloid precursor protein is determined by residues around the gamma-secretase cleavage sites. *J. Biol. Chem.* **2017**, *292*, 15826–15837. [[CrossRef](#)] [[PubMed](#)]
22. Shin, Y.; Cho, H.S.; Rebeck, G.W.; Greenberg, S.M. Vascular changes in Iowa-type hereditary cerebral amyloid angiopathy. *Ann. N. Y. Acad. Sci.* **2002**, *977*, 245–251. [[CrossRef](#)] [[PubMed](#)]
23. Qiang, W.; Yau, W.-M.; Luo, Y.; Mattson, M.P.; Tycko, R. Antiparallel β -sheet architecture in Iowa-mutant β -amyloid fibrils. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 4443–4448. [[CrossRef](#)] [[PubMed](#)]
24. Petkova, A.T.; Ishii, Y.; Balbach, J.J.; Antzutkin, O.N.; Leapman, R.D.; Delaglio, F.; Tycko, R. A structural model for Alzheimer's β -amyloid fibrils based on experimental constraints from solid state NMR. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 16742–16747. [[CrossRef](#)]
25. Murakami, K.; Irie, K.; Morimoto, A.; Ohigashi, H.; Shindo, M.; Nagao, M.; Shimizu, T.; Shirasawa, T. Neurotoxicity and physicochemical properties of A β mutant peptides from cerebral amyloid angiopathy—Implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. *J. Biol. Chem.* **2003**, *278*, 46179–46187. [[CrossRef](#)]
26. Hatami, A.; Monjazeb, S.; Milton, S.; Glabe, C.G. Familial Alzheimer's disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid- β peptide. *J. Biol. Chem.* **2017**, *292*, 3172–3185. [[CrossRef](#)]
27. Van Broeckhoven, C.; Haan, J.; Bakker, E.; Hardy, J.A.; Van Hul, W.; Wehnert, A.; Vegter-Van der Vlis, M.; Roos, R.A. Amyloid β protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). *Science* **1990**, *248*, 1120–1122. [[CrossRef](#)]
28. Van Nostrand, W.E.; Melchor, J.P.; Cho, H.S.; Greenberg, S.M.; Rebeck, G.W. Pathogenic effects of D23N Iowa mutant amyloid β -protein. *J. Biol. Chem.* **2001**, *276*, 32860–32866. [[CrossRef](#)]

29. Melchor, J.P.; Van Nostrand, W.E. Fibrillar amyloid β -protein mediates the pathologic accumulation of its secreted precursor in human cerebrovascular smooth muscle cells. *J. Biol. Chem.* **2000**, *275*, 9782–9791. [[CrossRef](#)]
30. Van Nostrand, W.E.; Melchor, J.P.; Romanov, G.; Zeigler, K.; Davis, J. Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid β -protein precursor. In *Alzheimer's Disease: Vascular Etiology and Pathology*; DeLaTorre, J.C., Kalaria, R., Nakajima, K., Nagata, K., Eds.; Wiley: New York, NY, USA, 2002; pp. 258–265.
31. Scheidt, H.A.; Morgado, I.; Huster, D. Solid-state NMR reveals a close structural relationship between amyloid- β protofibrils and oligomers. *J. Biol. Chem.* **2012**, *287*, 22822–22826. [[CrossRef](#)]
32. Fu, Z.; Aucoin, D.; Davis, J.; Van Nostrand, W.E.; Smith, S.O. Mechanism of nucleated conformational conversion of A β 42. *Biochemistry* **2015**, *54*, 4197–4207. [[CrossRef](#)] [[PubMed](#)]
33. Davis, J.; Xu, F.; Hatfield, J.; Lee, H.; Hoos, M.D.; Popescu, D.; Crooks, E.; Kim, R.; Smith, S.O.; Robinson, J.K.; et al. A novel transgenic rat model of robust cerebral microvascular amyloid with prominent vasculopathy. *Am. J. Pathol.* **2018**, *188*, 2877–2889. [[CrossRef](#)] [[PubMed](#)]
34. Crooks, E.J.; Irizarry, B.A.; Ziliox, M.; Kawakami, T.; Victor, T.; Xu, F.; Hojo, H.; Chiu, K.; Simmerling, C.; Van Nostrand, W.E.; et al. Copper stabilizes antiparallel β -sheet fibrils of the amyloid- β 40 (A β 40)-Iowa variant. *J. Biol. Chem.* **2020**, *295*, 8914–8927. [[CrossRef](#)] [[PubMed](#)]
35. Perczel, A.; Park, K.; Fasman, G.D. Deconvolution of the circular-dichroism spectra of proteins—the circular-dichroism spectra of the antiparallel β -sheet in proteins. *Proteins Struct. Funct. Genet.* **1992**, *13*, 57–69. [[CrossRef](#)] [[PubMed](#)]
36. Johnson, W.C. Protein secondary structure and circular-dichroism—A practical guide. *Proteins Struct. Funct. Genet.* **1990**, *7*, 205–214. [[CrossRef](#)]
37. Cerf, E.; Sarroukh, R.; Tamamizu-Kato, S.; Breydo, L.; Derclaye, S.; Dufrene, Y.F.; Narayanaswami, V.; Goormaghtigh, E.; Ruyschaert, J.M.; Raussens, V. Antiparallel β -sheet: A signature structure of the oligomeric amyloid β -peptide. *Biochem. J.* **2009**, *421*, 415–423. [[CrossRef](#)]
38. Tang, T.C.; Hu, Y.; Kienlen-Campard, P.; El Haylani, L.; Decock, M.; Van Hees, J.; Fu, Z.; Octave, J.N.; Constantinescu, S.N.; Smith, S.O. Conformational changes induced by the A21G Flemish mutation in the amyloid precursor protein lead to increased A β production. *Structure* **2014**, *22*, 387–396. [[CrossRef](#)]
39. Paul, C.; Wang, J.P.; Wimley, W.C.; Hochstrasser, R.M.; Axelsen, P.H. Vibrational coupling, isotopic editing, and β -sheet structure in a membrane-bound polypeptide. *J. Am. Chem. Soc.* **2004**, *126*, 5843–5850. [[CrossRef](#)]
40. Petty, S.A.; Decatur, S.M. Experimental evidence for the reorganization of β -strands within aggregates of the A β (16–22) peptide. *J. Am. Chem. Soc.* **2005**, *127*, 13488–13489. [[CrossRef](#)]
41. Van Vickle, G.D.; Esh, C.L.; Dausgs, I.D.; Kokjohn, T.A.; Kalback, W.M.; Patton, R.L.; Luehrs, D.C.; Walker, D.G.; Lue, L.F.; Beach, T.G.; et al. Tg-SwDI transgenic mice exhibit novel alterations in A β PP processing, A β degradation, and resilient amyloid angiopathy. *Am. J. Pathol.* **2008**, *173*, 483–493. [[CrossRef](#)]
42. Fu, Z.; Aucoin, D.; Ahmed, M.; Ziliox, M.; Van Nostrand, W.E.; Smith, S.O. Capping of A β 42 oligomers by small molecule inhibitors. *Biochemistry* **2014**, *53*, 7893–7903. [[CrossRef](#)] [[PubMed](#)]
43. Norlin, N.; Hellberg, M.; Filippov, A.; Sousa, A.A.; Gröbner, G.; Leapman, R.D.; Almqvist, N.; Antzutkin, O.N. Aggregation and fibril morphology of the Arctic mutation of Alzheimer's A β peptide by CD, TEM, STEM and in situ AFM. *J. Struct. Biol.* **2012**, *180*, 174–189. [[CrossRef](#)] [[PubMed](#)]
44. Yamaguchi, T.; Matsuzaki, K.; Hoshino, M. Transient formation of intermediate conformational states of amyloid- β peptide revealed by heteronuclear magnetic resonance spectroscopy. *FEBS Lett.* **2011**, *585*, 1097–1102. [[CrossRef](#)] [[PubMed](#)]
45. Shea, D.; Hsu, C.C.; Bi, T.M.; Paranjapye, N.; Childers, M.C.; Cochran, J.; Tomberlin, C.P.; Wang, L.B.; Paris, D.; Zonderman, J.; et al. alpha-Sheet secondary structure in amyloid β -peptide drives aggregation and toxicity in Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 8895–8900. [[CrossRef](#)] [[PubMed](#)]
46. Hu, Y.; Kienlen-Campard, P.; Tang, T.C.; Perrin, F.; Opsomer, R.; Decock, M.; Pan, X.S.; Octave, J.N.; Constantinescu, S.N.; Smith, S.O. β -Sheet structure within the extracellular domain of C99 regulates amyloidogenic processing. *Sci. Rep.* **2017**. [[CrossRef](#)]
47. Sandberg, A.; Luheshi, L.M.; Sollvander, S.; de Barros, T.P.; Macao, B.; Knowles, T.P.J.; Biverstal, H.; Lendel, C.; Ekholm-Pettersson, F.; Dubnovitsky, A.; et al. Stabilization of neurotoxic Alzheimer amyloid- β oligomers by protein engineering. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 15595–15600. [[CrossRef](#)]
48. Hard, T. Protein engineering to stabilize soluble amyloid β -protein aggregates for structural and functional studies. *FEBS J.* **2011**, *278*, 3884–3892. [[CrossRef](#)]
49. Hoyer, W.; Gronwall, C.; Jonsson, A.; Stahl, S.; Hard, T. Stabilization of a β -hairpin in monomeric Alzheimer's amyloid- β peptide inhibits amyloid formation. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 5099–5104. [[CrossRef](#)]
50. Sciarretta, K.L.; Gordon, D.J.; Petkova, A.T.; Tycko, R.; Meredith, S.C. A β 40-lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. *Biochemistry* **2005**, *44*, 6003–6014. [[CrossRef](#)]
51. Xiao, Y.; Ma, B.; McElheny, D.; Parthasarathy, S.; Long, F.; Hoshi, M.; Nussinov, R.; Ishii, Y. A β (1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. *Nat. Struct. Mol. Biol.* **2015**, *22*, 499–505. [[CrossRef](#)]
52. Colvin, M.T.; Silvers, R.; Ni, Q.Z.; Can, T.V.; Sergeev, I.; Rosay, M.; Donovan, K.J.; Michael, B.; Wall, J.; Linse, S.; et al. Atomic resolution structure of monomeric A β (42) amyloid fibrils. *J. Am. Chem. Soc.* **2016**, *138*, 9663–9674. [[CrossRef](#)] [[PubMed](#)]

53. Elkins, M.R.; Wang, T.; Nick, M.; Jo, H.; Lemmin, T.; Prusiner, S.B.; DeGrado, W.F.; Stohr, J.; Hong, M. Structural polymorphism of Alzheimer's β -amyloid fibrils as controlled by an E22 switch: A solid-state NMR study. *J. Am. Chem. Soc.* **2016**, *138*, 9840–9852. [[CrossRef](#)] [[PubMed](#)]
54. Masuda, Y.; Irie, K.; Murakami, K.; Ohigashi, H.; Ohashi, R.; Takegoshi, K.; Shimizu, T.; Shirasawa, T. Verification of the turn at positions 22 and 23 of the β -amyloid fibrils with Italian mutation using solid-state NMR. *Bioorganic Med. Chem.* **2005**, *13*, 6803–6809. [[CrossRef](#)]
55. Perez, C.; Miti, T.; Hasecke, F.; Meisl, G.; Hoyer, W.; Muschol, M.; Ullah, G. Mechanism of fibril and soluble oligomer formation in amyloid- β and hen egg white lysozyme proteins. *J. Phys. Chem. B* **2019**, *123*, 5678–5689. [[CrossRef](#)] [[PubMed](#)]
56. Mastrangelo, I.A.; Ahmed, M.; Sato, T.; Liu, W.; Wang, C.; Hough, P.; Smith, S.O. High-resolution atomic force microscopy of soluble A β 42 oligomers. *J. Mol. Biol.* **2006**, *358*, 106–119. [[CrossRef](#)]
57. Sarkar, B.; Mithu, V.S.; Chandra, B.; Mandal, A.; Chandrakesan, M.; Bhowmik, D.; Madhu, P.K.; Maiti, S. Significant structural differences between transient amyloid- β oligomers and less-toxic fibrils in regions known to harbor familial Alzheimer's mutations. *Angew. Chem. Int. Ed.* **2014**, *53*, 6888–6892. [[CrossRef](#)]
58. Tanzi, R.E.; Moir, R.D.; Wagner, S.L. Clearance of Alzheimer's A β peptide: The many roads to perdition. *Neuron* **2004**, *43*, 605–608.
59. Charidimou, A.; Boulouis, G.; Gurol, M.E.; Ayata, C.; Bacskai, B.J.; Frosch, M.P.; Viswanathan, A.; Greenberg, S.M. Emerging concepts in sporadic cerebral amyloid angiopathy. *Brain* **2017**, *140*, 1829–1850. [[CrossRef](#)]